Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: An indirect comparison of olodaterol and indacaterol

International Journal of COPD

Volumn 9, Issue , 2014, Pages 813-824

  Roskell, Neil S ^a   Anzueto, Antonio ^b   Hamilton, Alan ^c   Disse, Bernd ^d   Becker, Karin ^d  

^a BRESMED   (United Kingdom)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

COPD; Indacaterol; LABA; Meta analysis; Olodaterol; Systematic review

Indexed keywords

BRONCHODILATING AGENT; FORMOTEROL; INDACATEROL; OLODATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; BENZOXAZINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TRANSITION DYSPNEA INDEX; DRUG ADMINISTRATION; DRUG EFFECTS; LUNG; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BENZOXAZINES; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84905450100     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S59673     Document Type: Article

References (41)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6): 532-555.
2. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org/. Accessed March 7, 2013.
3. Mroz RM, Minarowski L, Chyczewska E. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients. Adv Exp Med Biol. 2013;756:23-28.
4. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102(11):1511-1520.
5. Mills EJ, Thorlund K, Ioannidis JP. Calculating additive treatment effects from multiple randomized trials provides useful estimates of combination therapies. J Clin Epidemiol. 2012;65(12):1282-1288.
6. McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs. 2012;72(4):543-563.
7. Donohue JF, Jones PW. Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:35-45.
8. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701-708.
9. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, UPLIFT investigaotrs. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet. 2009;374(9696):1171-1178.
10. Food and Drug Administration. Pulmonary-Allergy Drugs Advisory Committee Meeting: NDA 203108: Olodaterol (Proposed Trade Name Striverdi Respimat) for The Proposed Indication of Long-Term, Once-Daily Maintenance Bronchodilator Treatment of Airflow Obstruction in Patients with Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis and/or Emphysema; 2013. Available from: http://www. assets.fiercemarkets.com/public/lifesciences/pulmonary.pdf. Accessed March 28, 2013.
11. Novartis Pharmaceuticals Canada Inc. Onbrez Breezhaler [product monograph]; 2011 [updated 2012]. Available from: http://www.novartis.ca/products/en/pharmaceuticals-o.shtml. Accessed March 27, 2013.
12. Novartis Pharmaceuticals Corporation. Arcapta Neohaler [prescribing information]; 2012. Available from: http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/arcapta.pdf. Accessed March 27, 2013.
13. Novartis Europharm Limited. Summary of product characteristics for Onbrez Breezhaler; 2012. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001114/human_med_001219.jsp&mid=WC0b01ac058001d124. Accessed March 7, 2013.
14. National Institute for Health and Care Excellence. Specification for Manufacturer/Sponsor Submission Of Evidence; 2009. Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/SpecificationForManufacturerSponsorSubmissionOfEvidence.jsp. Accessed July 16, 2012.
15. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014:9:629-645.
16. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697-714.
17. Feldman GJ, Bernstein JA, Hamilton A, Nivens MC, Korducki L, LaForce C. The 24-h FEV1 Time Profile of Olodaterol Once Daily via Respimat® and Formoterol Twice Daily via Aerolizer® in Patients with GOLD 2-4 COPD: Results from Two 6-week Crossover Studies. Springer Plus. In press 2014.
18. Lange P, Aumann JL, Hamilton A, Tetzlaff K, Ting N, Derom E. The 24-hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Respir Med. In press 2014.
19. Centre for Reviews and Dissemination. CRD's Guidance for Undertaking Reviews in Health Care. University of York: Centre for Reviews and Dissemination; 2009. Available from: http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf. Accessed August 30, 2012.
20. Jones B, Roger J, Lane PW, et al. Statistical approaches for conducting network meta-analysis in drug development. Pharm Stat. 2011;10(6):523-531.
21. Whitehead A. Meta-Analysis of Controlled Clinical Trials. Chichester, West Sussex, England: John Wiley and Sons Ltd; 2002.
22. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683-691.
23. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326:472.
24. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomized, double-blind comparison. Thorax. 2012;67(9):781-788.
25. Kinoshita M, Lee S-H, Hang L-W, et al. Efficacy and safety of indacaterol 150 and 300g in Asian COPD patients: a 12-week, placebo controlled study. American Thoracic Society International Conference; May 13-18, 2011; Denver, Colorado. Abstract no A1593.
26. Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomized, placebo controlled clinical trial. Pulm Pharmacol Ther. 2007;20(6):740-749.
27. Study B2354. Reported in Center for Drug Evaluation and Research summary review document for indacaterol; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000TOC.cfm. Accessed January 4, 2012.
28. Study B2355. Reported in Center for Drug Evaluation and Research summary review document for indacaterol; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000TOC.cfm. Accessed January 4, 2012.
29. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-162.
30. Feldman G, Siler T, Prasad N, et al; INLIGHT 1 study group. Efficacy and safety of indacaterol 150 microg. once-daily in COPD: a double-blind, randomized, 12-week study. BMC Pulm Med. 2010;10:11.
31. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-279.
32. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011;105(5):719-726.
33. Buhl R, Dunn LJ, Disdier C, et al. INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797-803.
34. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-479.
35. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(6):e1000097.
36. Cope S, Capkun-Niggli G, Gale R, et al. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health. 2012;15(3):524-533.
37. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Revised 2011. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf. Accessed March 28, 2013.
38. Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model based approaches. Respir Res. 2011;12:54.
39. Bleecker ER, Siler T, Owen R, Kramer B. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data. Int J Chron Obstruct Pulmon Dis. 2011;6: 431-438.
40. Cope S, Capkun-Niggli G, Gale R, Jardim J, Jansen JP. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease - a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2011;6:329-344.
41. Cope S, Zhang J, Williams J, Jansen JP. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis. BMC Pulm Med. 2012;12:29.